• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
ImmuCell Corporation (ICCC) Stock Price, News & Analysis

ImmuCell Corporation (ICCC) Stock Price, News & Analysis

Currency in USD Disclaimer

$3.69

$0.03

(0.82%)

Day's range
$3.65
Day's range
$3.74
50-day range
$3.34
Day's range
$3.94
  • Country: US
  • ISIN: US4525253062
52 wk range
$3.34
Day's range
$5.59


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.18
  • Piotroski Score 4.00
  • Grade N/A
  • Symbol (ICCC)
  • Company ImmuCell Corporation
  • Price $3.69
  • Changes Percentage (0.82%)
  • Change $0.03
  • Day Low $3.65
  • Day High $3.74
  • Year High $5.59

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.51
  • Trailing P/E Ratio -8.8
  • Forward P/E Ratio -8.8
  • P/E Growth -8.8
  • Net Income $-5,774,598

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

ImmuCell Corporation Frequently Asked Questions

  • What is the ImmuCell Corporation stock price today?

    Today's price of ImmuCell Corporation is $3.69 — it has increased by +0.82% in the past 24 hours. Watch ImmuCell Corporation stock price performance more closely on the chart.

  • Does ImmuCell Corporation release reports?

    Yes, you can track ImmuCell Corporation's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the ImmuCell Corporation stock forecast?

    Watch the ImmuCell Corporation chart and read a more detailed ImmuCell Corporation stock forecast to see what analysts suggest you do with its shares.

  • What is ImmuCell Corporation stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by ImmuCell Corporation stock ticker.

  • How to buy ImmuCell Corporation stocks?

    Like other stocks, ICCC shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is ImmuCell Corporation's EBITDA?

    ImmuCell Corporation measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in ImmuCell Corporation’s financial statements.

  • What is the ImmuCell Corporation's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.3305120993, which equates to approximately -33.05%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in ImmuCell Corporation stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including ImmuCell Corporation's financials relevant news, and technical analysis. ImmuCell Corporation's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for ImmuCell Corporation stock currently indicates a “sell” signal. For more insights, review ImmuCell Corporation’s technical analysis.

  • A revenue figure for ImmuCell Corporation for its last quarter?

    ImmuCell Corporation published it's last quarterly revenues at $6.01 B.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.